We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

154 hedge funds and large institutions have $413M invested in Allogene Therapeutics in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 67 increasing their positions, 37 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

81% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 37

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less funds holding

Funds holding: 171 → 154 (-17)

13.74% less ownership

Funds ownership: 91.47% → 77.73% (-14%)

38% less capital invested

Capital invested by funds: $663M → $413M (-$250M)

55% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 29

58% less call options, than puts

Call options by funds: $195K | Put options by funds: $469K

Holders
154
Holders Change
-17
Holders Change %
-9.94%
% of All Funds
2.44%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
13
Increased
67
Reduced
37
Closed
29
Calls
$195K
Puts
$469K
Net Calls
-$274K
Net Calls Change
-$97K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$13.5M
2
JP Morgan Chase
JP Morgan Chase
New York
+$3.4M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.39M
4
BlackRock
BlackRock
New York
+$1.96M
5
CANY
Caxton Associates (New York)
New York
+$1.8M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12.8M
2
BBA
Baker Bros. Advisors
New York
-$7.84M
3
Cerity Partners
Cerity Partners
New York
-$2.97M
4
Two Sigma Investments
Two Sigma Investments
New York
-$2.86M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nordea Investment Management
26
Nordea Investment Management
Sweden
$2.42M -$47.4K -10,807 -1%
Norges Bank
27
Norges Bank
Norway
$2.06M -$522K -119,048 -15%
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$1.81M +$1.46M +332,660 +140%
CANY
29
Caxton Associates (New York)
New York
$1.52M +$1.8M +410,520 +590%
PCIG
30
Partners Capital Investment Group
Massachusetts
$1.44M – – –
Mirae Asset Global Investments
31
Mirae Asset Global Investments
South Korea
$1.36M +$144K +32,770 +8%
CBA
32
Coastal Bridge Advisors
Connecticut
$1.29M – – –
Voloridge Investment Management
33
Voloridge Investment Management
Florida
$1.27M -$480K -109,509 -21%
N
34
Nuveen
North Carolina
$1.14M +$102K +23,337 +7%
Citigroup
35
Citigroup
New York
$1.07M +$252K +57,392 +20%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$1.03M -$50.9K -11,610 -3%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$985K +$8.45K +1,928 +0.6%
RPAM
38
Rhenman & Partners Asset Management
Sweden
$951K – – –
Principal Financial Group
39
Principal Financial Group
Iowa
$844K +$19.9K +4,531 +2%
SAM
40
Simplify Asset Management
Nevada
$777K – – –
TD Asset Management
41
TD Asset Management
Ontario, Canada
$754K +$168K +38,357 +19%
Marshall Wace
42
Marshall Wace
United Kingdom
$725K +$812K +185,296 +427%
CSS
43
Cubist Systematic Strategies
Connecticut
$679K +$851K +194,241 +976%
UBS Group
44
UBS Group
Switzerland
$655K -$396K -90,253 -30%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$646K – – –
Swiss National Bank
46
Swiss National Bank
Switzerland
$610K +$24.5K +5,600 +3%
State of Wisconsin Investment Board
47
State of Wisconsin Investment Board
Wisconsin
$587K +$479K +109,245 +144%
Mitsubishi UFJ Asset Management
48
Mitsubishi UFJ Asset Management
Japan
$583K – – –
Wells Fargo
49
Wells Fargo
California
$536K +$14K +3,189 +2%
Schroder Investment Management Group
50
Schroder Investment Management Group
United Kingdom
$535K – – –
1
2
3 4 5

ALLO Hedge Fund Activity: Q3 2023 in Review

154 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2023, worth a combined $413M — down 38% from $663M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ALLO and 13 opened new positions — a net loss of 16 holders — while 37 trimmed existing stakes and 67 added.

The largest buyer was Vanguard Group, adding an estimated $13.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.8M.

  • 154 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2023, down from 171 in Q2 2023.
  • Funds reported $413M of Allogene Therapeutics stock for Q3 2023, down 38% quarter-over-quarter.
  • 13 funds opened new Allogene Therapeutics positions in Q3 2023 and 29 closed out, a net change of -16 holders.
  • The largest Allogene Therapeutics buyer in Q3 2023 was Vanguard Group, an estimated $13.5M added.
  • The largest Allogene Therapeutics seller in Q3 2023 was T. Rowe Price Associates, an estimated $12.8M sold.

Based on aggregated 13F filings for Q3 2023.